Treatment-Resistant Hypertension Management Market is expected to See Incredible Growth by 2033

The global Treatment-Resistant Hypertension Management Market is predicted to generate a market value of US$ 43 Million in 2023 and a market value of US$ 159.41 Million by 2033, with a CAGR of 14% from 2023 to 2033. From 2018 to 2022, the market for Treatment-Resistant Hypertension Management grew at a CAGR of 11%.

The growing prevalence of hypertension globally, as well as the expanding number of patients with Treatment-Resistant Hypertension, are driving the market for Treatment-Resistant Hypertension management. According to the World Health Organisation, hypertension is the biggest cause of cardiovascular illness and mortality in the world, impacting more than 1 billion people. The prevalence of Treatment-Resistant Hypertension is estimated to be 10% to 30% of all hypertensive individuals.

Treatment-Resistant Hypertension is often managed with a combination of antihypertensive drugs, including diuretics, beta-blockers, calcium channel blockers, angiotensin-converting enzyme (ACE) inhibitors, and angiotensin receptor blockers (ARBs). Many patients with Treatment-Resistant Hypertension, on the other hand, do not respond well to these drugs and may require more severe treatment options.

One of the primary factors driving the growth of the treatment-resistant hypertension management market is the rising prevalence of hypertension. Hypertension, often known as high blood pressure, is a chronic medical disorder characterised by chronically excessive blood pressure in the arteries. Hypertension is a key risk factor for cardiovascular disorders like heart disease and stroke, which are important sources of morbidity and mortality around the world.

Major Players:

Major players in the market include companies such as Competition Deep Dive, Janssen Biotech, Quantum Genomics SA, CinCor Pharma, Ionis Pharmaceuticals, Vifor Pharma, KBP Biosciences, Abbott, Kona Medical, Inc., Medtronic along with healthcare providers and technology companies among other global players.

Browse More Details@ https://www.futuremarketinsights.com/reports/Treatment-resistant-hypertension-management-market

Key Segments Profiled in the Treatment-Resistant Hypertension Management Industry Survey

Treatment:

  • Diuretic therapy
  • Combination therapy
  • Mineralocorticoid receptor antagonists

Distribution Channel:

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Comments

Post a Comment

Popular posts from this blog

Targeted Therapies for Sandhoff Disease | Assessing the Global Market Landscape

Image
The global Sandhoff Disease Therapeutics Market Size is expected to be worth US$ 10 million in 2023 and US$ 17.91 million by 2033, with a CAGR of 6% from 2023 to 2033. From 2018 to 2022, the Sandhoff Disease Treatments market increased at a 4% CAGR. According to the most recent studies, Sandhoff sickness is a rare disorder that affects 1 in 1,000,000 people. The rising demand for these medications is projected to spur the discovery of novel therapies, propelling the market forward in the coming years. Gene therapy is being investigated as a potential treatment for Sandhoff disease. The therapy restores the ability to break down GM2 ganglioside by delivering a functional copy of the missing enzyme into the patient's cells. This has the potential to reduce or stop disease progression while also improving patient quality of life. Key Takeaways from the Market Study   The Sandhoff Disease Therapeutics market increased at a 4% CAGR from 2018 to 2022. From 2023 to 2033, the global Sandh
Read more

A Safer Tomorrow | Emerging Trends in Hospital-Acquired Infection Control Market

Image
According to Future Market Insights' recently released Hospital-acquired Infection Control Market analysis report, global Hospital-acquired Infection Control sales in 2023 are expected to be US$ 6.5 billion. The market is expected to increase at a CAGR of 7% between 2023 and 2033, reaching $12.7 billion by 2033. Hospitals and intensive care units are predicted to create significant income in the market, with a CAGR of 7.6%. The occurrence of hospital-acquired infections, increasing proportion of surgical procedures, growing geriatric population and increasing prevalence of chronic diseases, technological advancements in sterilisation equipment, and growing awareness of environmental and personal hygiene are the key factors driving the Hospital-acquired infection control market. The increased use of e-beam sterilisation, as well as the reintroduction of ethylene oxide sterilisation, is predicted to increase demand for hospital-acquired infection management. The percentage of treatm
Read more

Transforming Trauma | Emerging Therapies and Interventions in Post-Traumatic Stress Disorder Treatment Market

Image
According to Future Market Insights, the Post-Traumatic Stress Disorder (PTSD) Treatment Market Sales would grow at a 5% CAGR between 2023 and 2033. By 2033, the global market for post-traumatic stress disorder (PTSD) therapy is expected to reach US$ 27.37 billion. The market's growth might be attributed to the increased prevalence of PTSD globally. According to the National Centre for PTSD, approximately 7-8% of the US population will develop PTSD at some point in their lives, with greater percentages among military veterans and persons who have experienced sexual assault or other types of trauma. The COVID-19 pandemic has also been highlighted as a possible cause of PTSD, with healthcare workers, first responders, and people immediately impacted by the virus being especially vulnerable. In addition, there is a growing emphasis on using digital therapies and other non-pharmacological techniques to treat PTSD. For example, virtual reality exposure treatment (VRET) has shown potent
Read more